Therapeutic safety monitoring: what to look for and when to look for it.
about
Carbamazepine-provoked hepatotoxicity and possible aetiopathological role of glutathione in the events. Retrospective review of old data and call for new investigation.New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety?Rational approach to treatment options for Lennox-Gastaut syndrome.Levetiracetam: a different approach to the pharmacotherapy of epilepsy.Antiepileptic drugs and suicidalityNow we know the drug of first choice--or do we?The adverse effects of antiepileptic drugs in children.Toxic epidermal necrolysis due to concomitant use of lamotrigine and valproic Acid.Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders.The evaluation of thyroid functions, thyroid antibodies, and thyroid volumes in children with epilepsy during short-term administration of oxcarbazepine and valproate.The effect of antiepileptic drugs on mitochondrial activity: a pilot study.The effects of levetiracetam on objective and subjective sleep parameters in healthy volunteers and patients with partial epilepsy.Genome-wide association study identifies common variants associated with pharmacokinetics of psychotropic drugs.Glutathione S-transferase M1 and T1 polymorphisms and the risk of mild hepatotoxicity induced by carbamazepine in a tunisian population study.
P2860
Q30728586-F05EDF52-C542-48AC-B2C6-6E2EE38092E1Q33949491-F4C1C3B1-2F85-4907-93DF-0E78A445EA52Q33971818-EC9A07E0-08AE-496D-A3DC-4D3D20D27F6DQ34533863-219C001D-36D5-4561-A9D0-320EEDC43628Q35026451-DF9A76FB-57FE-4BDD-8C7A-77AFA28E68D0Q36094656-F651A61B-3417-4510-8DBF-BFC1680A1D90Q36811532-34CC40A7-FB54-42D1-9DAB-343C926271EAQ37187073-AA9DF4F2-FC3A-4E3E-A974-50DF2693D3C2Q37965552-2E7B6D59-E1A5-4E67-9C56-C5298A41B803Q40268324-04739B7F-ADD0-47A0-AD9F-FFB1CD382649Q43088233-363E9414-D32A-4402-BE1E-FA20150E7811Q44130666-E29D15FC-F5B4-4CDB-84B7-3E515F0B0F0BQ50587017-36EE60B0-58D7-49F3-86A2-2331CAFE37E1Q54095539-BB15C84A-966D-4A13-86F3-33763F927B80
P2860
Therapeutic safety monitoring: what to look for and when to look for it.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
Therapeutic safety monitoring: what to look for and when to look for it.
@ast
Therapeutic safety monitoring: what to look for and when to look for it.
@en
Therapeutic safety monitoring: what to look for and when to look for it.
@nl
type
label
Therapeutic safety monitoring: what to look for and when to look for it.
@ast
Therapeutic safety monitoring: what to look for and when to look for it.
@en
Therapeutic safety monitoring: what to look for and when to look for it.
@nl
prefLabel
Therapeutic safety monitoring: what to look for and when to look for it.
@ast
Therapeutic safety monitoring: what to look for and when to look for it.
@en
Therapeutic safety monitoring: what to look for and when to look for it.
@nl
P2860
P1433
P1476
Therapeutic safety monitoring: what to look for and when to look for it.
@en
P2093
C L Harden
P2860
P304
P356
10.1111/J.1528-1157.2000.TB02945.X
P478
41 Suppl 8
P577
2000-01-01T00:00:00Z